Trials / Not Yet Recruiting
Not Yet RecruitingNCT06535685
A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA
A Single-centre, Prospective, Open-label, Single-arm Study of Romiplostim for the Treatment of Refractory Transfusion-dependent Non-severe Aplastic Anaemia (NSAA)
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Efficacy and safety of Romiplostim in the treatment of refractory transfusion-dependent NSAA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romiplostim | Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months. |
Timeline
- Start date
- 2024-08-02
- Primary completion
- 2025-03-30
- Completion
- 2025-12-31
- First posted
- 2024-08-02
- Last updated
- 2024-08-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06535685. Inclusion in this directory is not an endorsement.